Skip to content
Compass trials mark a milestone moment for the psychedelics sector episode artwork

Jul 21, 2025 12 min

Compass trials mark a milestone moment for the psychedelics sector

from Pathfinders in Biopharma

Compass Pathways CEO Kabir Nath believes psilocybin-based therapy could be transformational for patients with treatment-resistant depression—and his company is already preparing to deliver it at scale. Speaking at RBC Capital Markets’ Global Healthcare Conference, Nath shares his vision for Compass and the future of psilocybin therapy for treatment-resistant depression.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Compass trials mark a milestone moment for the psychedelics sector

0:00 12:35

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Pathfinders in Biopharma?

This episode is 12 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on July 21, 2025.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.